RYAH Group is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through its IoT dose-measuring devices and AI analytics, RYAH is focused on expanding understanding of the value of devices combined with data to positively impact the future treatment of patients for various medical conditions. A recent article discussing the company reads, “Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed to capture anonymous patient dosing and feedback, combined with detailed strain analytics, enabling customized dosing regiments. The company has secured numerous partnerships across the globe, including establishing a footprint in the UK, USA, Australia and Canada, and it has closed several deals in the European Union. The company’s Smart-Inhaler has been selected as the dose-measurement, dose-control and data analytics platform for a UK pain management study and one of the world’s most ambitious and largest clinical trials ever to be conducted in cannabis.”
To view the full article, visit https://ibn.fm/6Xa23
RYAH Group Inc.
RYAH Group is a leader in digital health care analytics and technology. By creating a suite of dose-measuring, IoT devices that capture data from seed to consumption, RYAH is positioned to unearth breakthrough discoveries capable of reshaping the understanding of plant-based medicine. For more information, visit the company’s website at https://www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork